The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has favored marketing authorization for the ranibizumab biosimilar (Byooviz, SB11) based on phase 3 study findings.
European Union authorities have recommended that ranibizumab ophthalmology biosimilar candidate Byooviz (SB11) be approved for commercialization. Byooviz was developed by Samsung Bioepis and references the blockbuster medication Lucentis, a Novartis product that garnered $1.93 billion in 2020 sales.
Officials for Samsung Bioepis and Biogen, which would market the agent, said a final approval on marketing would make this the first biosimilar for Lucentis to be commercialized in the European Union.
The recommendation for marketing approval was from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), and the final decision on marketing authorization would be made by the European Commission.
Ranibizumab counters the development of blood vessels that contribute to retinal disorders such as neovascular (wet) age-related macular degeneration, diabetic macular oedema, macular oedema related to retinal vein occlusion, proliferative diabetic retinopathy, and choroidal neovascularization.
Officials said the positive CHMP opinion was based on successful phase 3 trial data demonstrating that outcomes for the biosimilar candidate were within prespecified margins for conformance with the originator product.
Mean changes from baseline in best corrected visual acuity and in central subfield thickness were measured. “The improvements in the primary efficacy outcomes remained stable and appeared comparable between treatment groups at all time points up to week 52,” officials said.
An application for Byooviz marketing authorization has been under review by the FDA since November 2020. Samsung Bioepis and Biogen are also seeking to commercialize an aflibercept biosimilar candidate (SB15), which is currently in phase 3 trial evaluation.
Aflibercept also is a vascular endothelial growth factor inhibitor and is employed in the treatment of macular degeneration and metastatic colorectal cancer. There are currently no biosimilars for this product, which was developed by Regeneron Pharmaceuticals and is sold under the brand names Eylea and Zaltrap.
For more reading on Samsung Bioepis and its biosimilars initiative, click here.
For a report on a recent paper on anti–tumor necrosis factor inhibitors by Biogen investigators, click here.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.